Rusan, a technology-driven company, has always been a leader in bringing superior quality and innovative technologies to India. In order to become the world’s fastest growing innovative company, Rusan Pharma is setting up a state-of-the art research centre in the Kandla Special Economic Zone which will focus on new deliver forms – especially nanotechnology and sustained release formulations.
Their focus will also be on neglected and orphan diseases such as – dengue, malaria, multi-drug resistant tuberculosis, and central nervous system diseases such as – parkinson’s, alzheimer’s and schizophrenia. The R&D centre will focus on API synthesis using newer bio-/nano/stereo-selective catalysts with the aim of bringing down production cost, increasing yield, purity and safety in production.
Rusan’s strengths of vertical integration lies in discovery, research, process chemistry, active pharmaceutical ingredient production, formulation development and regulatory filings. Rusan Pharmaceuticals is committed towards achieving its vision of becoming an innovation-led transnational pharmaceutical company.
Rusan has been a major player in the field of drug addiction treatment by supporting various NGOs across India and is also helping them by providing medicines required for treatment.
Rusan is one of the few companies in India and globally to have all the products in all the latest drug delivery formulations required for the treatment of drug, alcohol and tobacco addiction treatment. Rusan is a global leader in pain management products catering from mild to severe pain with products such as Fentanyl and Buprenorphine
Tarnsdermal Patches, Nalbuphine, morphine injections, tramadolparacetamoloro- dispersable tablets.